Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IDC-GP Pharm has got license to market and distribute CEL-SCI's experimental cancer drug Multikine (Leukocyte Interleukin, Injection) in Argentina and Venezuela.
Subscribe to our email newsletter
Multikine is currently being developed as a treatment for head and neck cancer.
Currently, CEL-SCI has existing licensing deals for Multikine with Teva Pharmaceuticals, Orient Europharma and Byron Pharmaceuticals.
Pursuant to the agreement, IDC-GP Pharm will be responsible for receiving regulatory approval to use Multikine in the territory.
Following the approval for the drug in any of the two countries, CEL-SCI will be responsible for manufacturing the product, while IDC-GP Pharm will be responsible for sales in the territory.
CEL-SCI CEO Geert Kersten said this agreement is consistent with CEL-SCI’s strategy to license Multikine in the emerging markets.